PRESERVATIVES

Are they safe?

31 May 2010

Piotr Kozarewicz
European Medicines Agency
Key Principles - Excipients

Most experts agree that formulations for the paediatric population may need to be different to those for adults:

- Formulations should be as simple as possible
- Number of excipients should be reduced to a minimum
- No unnecessary additives
- Excipient levels should be reduced to a minimum
Key Principles - Preservatives


“Antimicrobial preservatives are normally added to prevent microbial proliferation arising under in use conditions. The properties are due to certain chemical groups which are usually harmful to living cells and might therefore be associated to certain risks when used in man.”
Key Principles - Preservatives

“Inclusion of antimicrobial preservatives or antioxidants in a finished product needs special justification.

The use of these substances should be avoided in general, especially when considering the suitability of related formulations to the paediatric population.”
Problem?

We have the Guideline ...

so what is the problem?
Problem with Preservatives

Safety concerns?

Are the accumulated safety data relevant to the paediatric population?

Should we ban them in paediatric formulations?

What about existing formulations?
Problem with Preservatives

- Preservatives
  - May cause their own undesirable effects
  - They may be tolerated in adults but what about the paediatric population?
  - It is nearly always technically possible to re-think the product development to remove them or minimise their use
Policy making

No simple answer - difficult to deliver a single dogmatic view on the problem.

Strong Negative position
- Banned in ALL paediatric age groups? Or only in the Lower age groups e.g. neonates & infants?
- Banned for Long-term continuous use only?

Relaxed position
- OK for older children – but how old?
- For Short term use are we not concerned?
Safety of Preservatives

- Look at EU Food Legislation as a possible indicator of long-term safety
- Look at EU Food Safety Agency (EFSA) Scientific Committee Reports

Example:
Propyl paraben is not recommended in the food legislation.

Provisional conclusion – parabens should not be used in paediatric medicines for long term use. An extreme position considering many medicines already on the EU market with parabens - but do we want to keep on repeating this? A worthy aim to keep in mind.
Safety of Preservatives

Methyl & Ethyl parabens
EFSA has assigned ADI of 10mg/kg/day

Propyl paraben
EFSA has not assigned an ADI

Reports of developmental problems in juvenile animals. Failure of testicular development. Must be seen as relevant to paediatric use, esp. lower age groups.

Optimal approach - propyl paraben should not be used in paediatric medicines for neonates, infants and small children. Not even in the short term.
Safety of Preservatives

Other preservatives

**Benzoic acid and its salts**
Signals suggesting effect on activity and attention in children, however their relevance has not been evaluated nor confirmed.

Currently approved for use as food additive.

**Sorbic acid and its salts**
Currently approved for use as food additive.
Preservatives in eye drops

**Ophthalmic preparations** without preservatives **are strongly recommended** for use in paediatric patients, especially neonates. Therefore, pharmaceutical companies should develop preparations without preservatives wherever possible in order to cater for the diversity of patients’ needs.

Nevertheless, based on a review of available safety evidence, a general recommendation not to use preservatives in eye drops cannot be supported.

EMEA Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use (Doc. Ref.: EMEA/622721/2009)
Current approach ...

- Preservative free formulations whenever possible should be considered.

Instead of developing multidose liquid formulations requiring preservation alternatives such as solid dosage forms (granulates, granules in sachets, bulk granules in bottles with measuring devices, individual “dry” doses that can be converted to liquid immediately prior to use, etc) should be investigated
Current approach ...

- When preservatives are required, the concentration should be at the minimum level consistent with satisfactory antimicrobial function in each individual preparation and a thorough justification for the choice of the preservative should be provided.

- Non-clinical and clinical studies of appropriate design and duration are needed to give reassurance that the proposed formulations are optimal in terms of benefit/risk balance.
Future ...

A lot of unanswered questions:

We have to find a balance between a strong and relaxed position on formulation issues, keeping in mind:

- The need to have high quality appropriate pharmaceutical formulations for a sensitive population with special needs
- The “precautionary principle”
- Benefit/Risk arguments
- The need to be consistent
Thank you for the attention